Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Selenosemicarbazone Metal Complexes as Potential Metal-based Drugs

Author(s): Santiago Rostán, Graciela Mahler and Lucía Otero*

Volume 30, Issue 5, 2023

Published on: 26 January, 2022

Page: [558 - 572] Pages: 15

DOI: 10.2174/0929867329666211222115035

Price: $65

Abstract

The discovery of the anticancer activity of cisplatin has marked the emergence of modern Inorganic Medicinal Chemistry. This field of research is concerned with the application of inorganic compounds to therapy or diagnosis of disease. In particular, metal coordination of bioactive ligands has gained recognition in drug design. The interaction between transition metal ions and the organic drugs could enhance their diagnostic and therapeutic potentials by improving the stability and/or bioavailability or by achieving a metal-drug synergism through a dual or multiple mechanisms of action. The isosteric replacement of sulfur by selenium in thiosemicarbazones leads to selenosemicarbazones. This class of compounds exhibits numerous biological activities like antitumor, antimicrobial, antiviral, etc. and, in most cases, they were more pronounced in comparison to the sulfur analogues. On the other hand, while the effect of transition metal complexation on the biological activity of thiosemicarbazones has been widely studied, the pharmacological activity of the corresponding metal-selenosemicarbazone compounds has been less explored. In this work, the most relevant results related to the selenosemicarbazone metal complexes as potential metal-based drugs have been reviewed.

Keywords: Selenosemicarbazone, metal-based drugs, antitumor, antimicrobial, antiparasitic, metal complexes.

« Previous Next »
[1]
Papp, L.V.; Holmgren, A.; Khanna, K.K. Selenium and selenoproteins in health and disease. Antioxid. Redox Signal., 2010, 12(7), 793-795.
[http://dx.doi.org/10.1089/ars.2009.2973] [PMID: 19905883]
[2]
Wrobel, J.K.; Power, R.; Toborek, M. Biological activity of selenium: Revisited. IUBMB Life, 2016, 68(2), 97-105.
[http://dx.doi.org/10.1002/iub.1466] [PMID: 26714931]
[3]
Reich, H.J.; Hondal, R.J. Why nature chose selenium. ACS Chem. Biol., 2016, 11(4), 821-841.
[http://dx.doi.org/10.1021/acschembio.6b00031] [PMID: 26949981]
[4]
Rocha, J.B.; Piccoli, B.C.; Oliveira, C.S. Biological and chemical interest in selenium: A brief historical account. ARKIVOC, 2016, 2017, 457-491.
[http://dx.doi.org/10.24820/ark.5550190.p009.784]
[5]
Böck, A.; Forchhammer, K.; Heider, J.; Leinfelder, W.; Sawers, G.; Veprek, B.; Zinoni, F. Selenocysteine: The 21st amino acid. Mol. Microbiol., 1991, 5(3), 515-520.
[http://dx.doi.org/10.1111/j.1365-2958.1991.tb00722.x] [PMID: 1828528]
[6]
Romero, H.; Zhang, Y.; Gladyshev, V.N.; Salinas, G. Evolution of selenium utilization traits. Genome Biol., 2005, 6(8), R66.
[http://dx.doi.org/10.1186/gb-2005-6-8-r66] [PMID: 16086848]
[7]
Jones, J.B.; Stadtman, T.C. Selenium-dependent and selenium-independent formate dehydrogenases of Methanococcus vannielii. Separation of the two forms and characterization of the purified selenium-independent form. J. Biol. Chem., 1981, 256(2), 656-663.
[http://dx.doi.org/10.1016/S0021-9258(19)70024-6] [PMID: 7451465]
[8]
Khangulov, S.V.; Gladyshev, V.N.; Dismukes, G.C.; Stadtman, T.C. Selenium-containing formate dehydrogenase H from Escherichia coli: A molybdopterin enzyme that catalyzes formate oxidation without oxygen transfer. Biochemistry, 1998, 37(10), 3518-3528.
[http://dx.doi.org/10.1021/bi972177k] [PMID: 9521673]
[9]
Yamazaki, S. A selenium-containing hydrogenase from Methanococcus vannielii. Identification of the selenium moiety as a selenocysteine residue. J. Biol. Chem., 1982, 257(14), 7926-7929.
[http://dx.doi.org/10.1016/S0021-9258(18)34271-6] [PMID: 6211447]
[10]
Garcin, E.; Vernede, X.; Hatchikian, E.C.; Volbeda, A.; Frey, M.; Fontecilla-Camps, J.C. The crystal structure of a reduced [NiFeSe] hydrogenase provides an image of the activated catalytic center. Structure, 1999, 7(5), 557-566.
[http://dx.doi.org/10.1016/S0969-2126(99)80072-0] [PMID: 10378275]
[11]
Lee, B.C.; Lobanov, A.V.; Marino, S.M.; Kaya, A.; Seravalli, J.; Hatfield, D.L.; Gladyshev, V.N.A. A 4-selenocysteine, 2-selenocysteine insertion sequence (SECIS) element methionine sulfoxide reductase from Metridium senile reveals a non-catalytic function of selenocysteines. J. Biol. Chem., 2011, 286(21), 18747-18755.
[http://dx.doi.org/10.1074/jbc.M111.229807] [PMID: 21393246]
[12]
Yamashita, Y.; Yamashita, M. Identification of a novel selenium-containing compound, selenoneine, as the predominant chemical form of organic selenium in the blood of bluefin tuna. J. Biol. Chem., 2010, 285(24), 18134-18138.
[http://dx.doi.org/10.1074/jbc.C110.106377] [PMID: 20388714]
[13]
Weekley, C.M.; Harris, H.H. Which form is that? The importance of selenium speciation and metabolism in the prevention and treatment of disease. Chem. Soc. Rev., 2013, 42(23), 8870-8894.
[http://dx.doi.org/10.1039/c3cs60272a] [PMID: 24030774]
[14]
Lacourciere, G.M. Biosynthesis of selenophosphate. Biofactors, 1999, 10(2-3), 237-244.
[http://dx.doi.org/10.1002/biof.5520100222] [PMID: 10609888]
[15]
Ehrenreich, A.; Forchhammer, K.; Tormay, P.; Veprek, B.; Böck, A. Selenoprotein synthesis in E. coli. Purification and characterisation of the enzyme catalysing selenium activation. Eur. J. Biochem., 1992, 206(3), 767-773.
[http://dx.doi.org/10.1111/j.1432-1033.1992.tb16983.x] [PMID: 1606960]
[16]
Hosnedlova, B.; Kepinska, M.; Skalickova, S.; Fernandez, C.; Ruttkay-Nedecky, B.; Malevu, T.D.; Sochor, J.; Baron, M.; Melcova, M.; Zidkova, J.; Kizek, R. A summary of new findings on the biological effects of selenium in selected animal species-A critical review. Int. J. Mol. Sci., 2017, 18(10), 2209.
[http://dx.doi.org/10.3390/ijms18102209] [PMID: 29065468]
[17]
Ruberte, A.C.; Sanmartin, C.; Aydillo, C.; Sharma, A.K.; Plano, D. Development and therapeutic potential of selenazo compounds. J. Med. Chem., 2020, 63(4), 1473-1489.
[http://dx.doi.org/10.1021/acs.jmedchem.9b01152] [PMID: 31638805]
[18]
Filipović, N.R.; Bjelogrlić, S.K.; Pelliccia, S.; Jovanović, V.B.; Kojić, M.; Senćanski, M.; La Regina, G.; Silvestri, R.; Muller, C.D.; Todorović, T.R. Selenotriapine – An isostere of the most studied thiosemicarbazone with pronounced pro-apoptotic activity, low toxicity and ability to challenge phenotype reprogramming of 3-d mammary adenocarcinoma tumors. Arab. J. Chem., 2020, 13, 1466-1489.
[http://dx.doi.org/10.1016/j.arabjc.2017.11.017]
[19]
Calcatierra, V.; López, Ó.; Fernández-Bolaños, J.G.; Plata, G.B.; Padrón, J.M. Phenolic thio- and selenosemicarbazones as multi-target drugs. Eur. J. Med. Chem., 2015, 94, 63-72.
[http://dx.doi.org/10.1016/j.ejmech.2015.02.037] [PMID: 25752525]
[20]
Turk, S.R.; Shipman, C., Jr; Drach, J.C. Structure-activity relationships among alpha-(N)-heterocyclic acyl thiosemicarbazones and related compounds as inhibitors of herpes simplex virus type 1-specified ribonucleoside diphosphate reductase. J. Gen. Virol., 1986, 67(Pt 8), 1625-1632.
[http://dx.doi.org/10.1099/0022-1317-67-8-1625] [PMID: 3016157]
[21]
Klayman, D.L.; Scovill, J.P.; Bartosevich, J.F.; Bruce, J. 2-Acetylpyridine thiosemicarbazones. 5. 1-[1-(2-Pyridyl)ethyl]-3-thiosemicarbazides as potential antimalarial agents. J. Med. Chem., 1983, 26(1), 35-39.
[http://dx.doi.org/10.1021/jm00355a008] [PMID: 6338234]
[22]
Pizzo, C.; Faral-Tello, P.; Salinas, G.; Fló, M.; Robello, C.; Wipf, P.; Graciela Mahler, S. Selenosemicarbazones as potent cruzipain inhibitors and their antiparasitic properties against trypanosoma cruzi. MedChemComm, 2012, 3, 362.
[http://dx.doi.org/10.1039/c2md00283c]
[23]
Pizzo, C.; Faral-Tello, P.; Yaluff, G.; Serna, E.; Torres, S.; Vera, N.; Saiz, C.; Robello, C.; Mahler, G. New approach towards the synthesis of selenosemicarbazones, useful compounds for Chagas’ disease. Eur. J. Med. Chem., 2016, 109, 107-113.
[http://dx.doi.org/10.1016/j.ejmech.2015.12.040] [PMID: 26774036]
[24]
Al-Eisawi, Z.; Stefani, C.; Jansson, P.J.; Arvind, A.; Sharpe, P.C.; Basha, M.T.; Iskander, G.M.; Kumar, N.; Kovacevic, Z.; Lane, D.J.R.; Sahni, S.; Bernhardt, P.V.; Richardson, D.R.; Kalinowski, D.S. Novel mechanism of cytotoxicity for the selective selenosemicarbazone, 2-acetylpyridine 4,4-dimethyl-3-selenosemicarbazone (Ap44mse): Lysosomal membrane permeabilization. J. Med. Chem., 2016, 59(1), 294-312.
[http://dx.doi.org/10.1021/acs.jmedchem.5b01399] [PMID: 26645570]
[25]
Kowol, C.R.; Eichinger, R.; Jakupec, M.A.; Galanski, M.; Arion, V.B.; Keppler, B.K. Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones. J. Inorg. Biochem., 2007, 101(11-12), 1946-1957.
[http://dx.doi.org/10.1016/j.jinorgbio.2007.07.026] [PMID: 17825917]
[26]
Huls, R.; Renson, M. La sélénosemicarbazide et ses dérivés II. Préparation de sélénosemicarbazones et phényl-4 sélénosemicarbazones. Bull. Soc. Chim. Belg., 2010, 65, 684-695.
[http://dx.doi.org/10.1002/bscb.19560650707]
[27]
Pavon, J.M.C.; Pino, F. Comparative study of analytical properties and applications of picolinaldehyde thiosemicarbazone and selenosemicarbazone. Talanta, 1972, 19(12), 1659-1663.
[http://dx.doi.org/10.1016/0039-9140(72)80242-X] [PMID: 18961229]
[28]
Chen, Z.; Li, D.; Xu, N.; Fang, J.; Yu, Y.; Hou, W.; Ruan, H.; Zhu, P.; Ma, R.; Lu, S.; Cao, D.; Wu, R.; Ni, M.; Zhang, W.; Su, W.; Ruan, B.H. Novel 1,3,4-selenadiazole-containing kidney-type glutaminase inhibitors showed improved cellular uptake and antitumor activity. J. Med. Chem., 2019, 62(2), 589-603.
[http://dx.doi.org/10.1021/acs.jmedchem.8b01198] [PMID: 30543285]
[29]
Koketsu, M.; Yamamura, Y.; Ishihara, H. Synthesis of selenosemicarbazides and 1,2,4-triazoles. Heterocycles, 2006, 68, 1191.
[http://dx.doi.org/10.3987/COM-06-10725]
[30]
Bippus, P.; Molter, A.; Müller, D.; Mohr, F. Cyclohexanone selenosemicarbazone: A convenient starting material for the preparation of functionalised selenosemicarbazones and their pt and pd complexes. J. Organomet. Chem., 2010, 695, 1657-1662.
[http://dx.doi.org/10.1016/j.jorganchem.2010.03.029]
[31]
Tomar, N.; Hashmi, M.A.; Hashmi, A.A. Multifunctional nanomedicine. In: Advances in Metallodrugs; Islam, Shahid-ul-Hashmi; Hashmi, A.A.; Khan, S.A., Eds.; Wiley, 2020; pp. 363-401.
[http://dx.doi.org/10.1002/9781119640868.ch12]
[32]
Yousuf, I.; Bashir, M.; Arjmand, F.; Tabassum, S. Advancement of metal compounds as therapeutic and diagnostic metallodrugs: Current frontiers and future perspectives. Coord. Chem. Rev., 2021, 445, 214104.
[http://dx.doi.org/10.1016/j.ccr.2021.214104]
[33]
Barry, N.P.E.; Sadler, P.J. 100 years of metal coordination chemistry: From alfred werner to anticancer metallodrugs. Pure Appl. Chem., 2014, 86, 1897-1910.
[http://dx.doi.org/10.1515/pac-2014-0504]
[34]
Mjos, K.D.; Orvig, C. Metallodrugs in medicinal inorganic chemistry. Chem. Rev., 2014, 114(8), 4540-4563.
[http://dx.doi.org/10.1021/cr400460s] [PMID: 24456146]
[35]
Sodhi, R.K. Metal complexes in medicine: An overview and update from drug design perspective. Cancer Ther. Oncol. Int. J., 2019, 14.
[http://dx.doi.org/10.19080/CTOIJ.2019.14.555883]
[36]
Boros, E.; Dyson, P.J.; Gasser, G. Classification of metal-based drugs according to their mechanisms of action. Chem, 2020, 6(1), 41-60.
[http://dx.doi.org/10.1016/j.chempr.2019.10.013] [PMID: 32864503]
[37]
Prajapati, N.P.; Patel, H.D. Novel thiosemicarbazone derivatives and their metal complexes: Recent development. Synth. Commun., 2019, 1-38.
[http://dx.doi.org/10.1080/00397911.2019.1649432]
[38]
Bonaccorso, C.; Marzo, T.; La Mendola, D. Biological applications of thiocarbohydrazones and their metal complexes: A perspective review. Pharmaceuticals (Basel), 2019, 13(1), 4.
[http://dx.doi.org/10.3390/ph13010004] [PMID: 31881715]
[39]
Lobana, T.S.; Sharma, R.; Bawa, G.; Khanna, S. Bonding and structure trends of thiosemicarbazone derivatives of metals-an overview. Coord. Chem. Rev., 2009, 253, 977-1055.
[http://dx.doi.org/10.1016/j.ccr.2008.07.004]
[40]
Pal, I.; Basuli, F.; Bhattacharya, S. Thiosemicarbazone complexes of the platinum metals. A story of variable coordination modes. J. Chem. Sci., 2002, 114, 255-268.
[http://dx.doi.org/10.1007/BF02703818]
[41]
Molter, A.; Bill, E.; Mohr, F. Synthesis, structures and reactivity of two oxidovanadium(IV) and dioxidovanadium(V) selenosemicarbazonato complexes. Inorg. Chem. Commun., 2012, 17, 124-127.
[http://dx.doi.org/10.1016/j.inoche.2011.12.031]
[42]
Molter, A.; Mohr, F. Synthesis, structures and reactivity of some mono- and dinuclear palladium(ii) and platinum(ii) complexes containing 2-pyridyl functionalised selenosemicarbazones. Polyhedron, 2016, 120, 118-123.
[http://dx.doi.org/10.1016/j.poly.2016.07.016]
[43]
Molter, A.; Mohr, F. Indium(III), antimony(III) and bismuth(III) dihalide complexes with tridentate, anionic thio- and selenosemicarbazonato ligands. Dalton Trans., 2011, 40(14), 3754-3758.
[http://dx.doi.org/10.1039/c0dt01693d] [PMID: 21380464]
[44]
Todorović, T.R.; Bacchi, A.; Juranić, N.O.; Sladić, D.M.; Pelizzi, G.; Božić, T.T.; Filipović, N.R.; Anđelković, K.K. Synthesis and characterization of novel Cd(II), Zn(II) and Ni(II) Complexes with 2-quinolinecarboxaldehyde selenosemicarbazone. Crystal structure of Bis(2-quinolinecarboxaldehyde selenosemicarbazonato)nickel(II). Polyhedron, 2007, 26, 3428-3436.
[http://dx.doi.org/10.1016/j.poly.2007.03.023]
[45]
Dekanski, D.; Todorovic, T.; Mitic, D.; Filipovic, N.; Polovic, N.; Andjelkovic, K. High antioxidative potential and low toxic effects of selenosemicarbazone metal complexes. J. Serb. Chem. Soc., 2013, 78, 1503-1512.
[http://dx.doi.org/10.2298/JSC130315035D]
[46]
Todorović, T.R.; Vukašinović, J.; Portalone, G.; Suleiman, S.; Gligorijević, N.; Bjelogrlić, S.; Jovanović, K.; Radulović, S.; Anđelković, K.; Cassar, A.; Filipović, N.R.; Schembri-Wismayer, P. (Chalcogen)semicarbazones and their cobalt complexes differentiate HL-60 myeloid leukaemia cells and are cytotoxic towards tumor cell lines. MedChemComm, 2016, 8(1), 103-111.
[http://dx.doi.org/10.1039/C6MD00501B] [PMID: 30108695]
[47]
Bjelogrlić, S.; Todorović, T.; Bacchi, A.; Zec, M.; Sladić, D.; Srdić-Rajić, T.; Radanović, D.; Radulović, S.; Pelizzi, G.; Andelković, K. Synthesis, structure and characterization of novel Cd(II) and Zn(II) complexes with the condensation product of 2-formylpyridine and selenosemicarbazide Antiproliferative activity of the synthesized complexes and related selenosemicarbazone complexes. J. Inorg. Biochem., 2010, 104(6), 673-682.
[http://dx.doi.org/10.1016/j.jinorgbio.2010.02.009] [PMID: 20356629]
[48]
Filipović, N.; Polović, N.; Rašković, B.; Misirlić-Denčić, S.; Dulović, M.; Savić, M.; Nikšić, M.; Mitić, D.; Anđelković, K.; Todorović, T. Biological activity of two isomeric n-heteroaromatic selenosemicarbazones and their metal complexes. Monatshefte für chem. - chem. mon., 2014, 145, 1089-1099.
[http://dx.doi.org/10.1007/s00706-014-1197-6]
[49]
Filipović, N.R.; Bjelogrlić, S.; Marinković, A.; Verbić, T.Ž.; Cvijetić, I.N.; Senćanski, M.; Rodić, M.; Vujčić, M.; Sladić, D.; Striković, Z.; Todorović, T.R.; Muller, C.D. Zn(II) complex with 2-quinolinecarboxaldehyde selenosemicarbazone: synthesis, structure, interaction studies with dna/hsa, molecular docking and caspase-8 and -9 independent apoptose induction. RSC Advances, 2015, 5, 95191-95211.
[http://dx.doi.org/10.1039/C5RA19849F]
[50]
Filipović, N.R.; Bjelogrlić, S.; Portalone, G.; Pelliccia, S.; Silvestri, R.; Klisurić, O.; Senćanski, M.; Stanković, D.; Todorović, T.R.; Muller, C.D. Pro-apoptotic and pro-differentiation induction by 8-quinolinecarboxaldehyde selenosemicarbazone and its Co(III) complex in human cancer cell lines. MedChemComm, 2016, 7, 1604-1616.
[http://dx.doi.org/10.1039/C6MD00199H]
[51]
Gligorijević, N.; Todorović, T.; Radulović, S.; Sladić, D.; Filipović, N.; Gođevac, D.; Jeremić, D.; Andelković, K. Synthesis and characterization of new Pt(II) and Pd(II) complexes with 2-quinolinecarboxaldehyde selenosemicarbazone: cytotoxic activity evaluation of Cd(II), Zn(II), Ni(II), Pt(II) and Pd(II) complexes with heteroaromatic selenosemicarbazones. Eur. J. Med. Chem., 2009, 44(4), 1623-1629.
[http://dx.doi.org/10.1016/j.ejmech.2008.07.033] [PMID: 18789831]
[52]
Molter, A.; Kaluđerović, G.N.; Kommera, H.; Paschke, R.; Langer, T.; Pöttgen, R.; Mohr, F. Synthesis, structures, 119sn mössbauer spectroscopic studies and biological activity of some tin(iv) complexes containing pyridyl functionalised selenosemicarbazonato ligands. J. Organomet. Chem., 2012, 701, 80-86.
[http://dx.doi.org/10.1016/j.jorganchem.2011.12.027]
[53]
Enyedy, É.A.; May, N.V.; Pape, V.F.S.; Heffeter, P.; Szakács, G.; Keppler, B.K.; Kowol, C.R. Complex formation and cytotoxicity of Triapine derivatives: A comparative solution study on the effect of the chalcogen atom and NH-methylation. Dalton Trans., 2020, 49(46), 16887-16902.
[http://dx.doi.org/10.1039/D0DT03465G] [PMID: 33185224]
[54]
Zec, M.; Srdic-Rajic, T.; Krivokuca, A.; Jankovic, R.; Todorovic, T.; Andelkovic, K.; Radulovic, S. Novel selenosemicarbazone metal complexes exert anti-tumor effect via alternative, caspase-independent necroptotic cell death. Med. Chem., 2014, 10(8), 759-771.
[http://dx.doi.org/10.2174/1573406410666140327122009] [PMID: 24678785]
[55]
Al-Harbi, S.A.; Al-Saidi, H.M.; Debbabi, K.F.; Allehyani, E.S.; Alqorashi, A.A.; Emara, A.A.A. Design and anti-tumor evaluation of new platinum(ii) and copper(ii) complexes of nitrogen compounds containing selenium moieties. J. Saudi Chem. Soc., 2020, 24, 982-995.
[http://dx.doi.org/10.1016/j.jscs.2020.10.006]
[56]
Srdić-Rajić, T.; Zec, M.; Todorović, T.; Anđelković, K.; Radulović, S. Non-substituted N-heteroaromatic selenosemicarbazone metal complexes induce apoptosis in cancer cells via activation of mitochondrial pathway. Eur. J. Med. Chem., 2011, 46(9), 3734-3747.
[http://dx.doi.org/10.1016/j.ejmech.2011.05.039] [PMID: 21641698]
[57]
Zec, M.; Srdic-Rajic, T.; Konic-Ristic, A.; Todorovic, T.; Andjelkovic, K.; Filipovic-Ljeskovic, I.; Radulovic, S. Anti-metastatic and anti-angiogenic properties of potential new anti-cancer drugs based on metal complexes of selenosemicarbazones. Anticancer. Agents Med. Chem., 2012, 12(9), 1071-1080.
[http://dx.doi.org/10.2174/187152012803529682] [PMID: 22583413]
[58]
Perez-Rebolledo, A.; Ayala, J.D.; de Lima, G.M.; Marchini, N.; Bombieri, G.; Zani, C.L.; Souza-Fagundes, E.M.; Beraldo, H. Structural studies and cytotoxic activity of N(4)-phenyl-2-benzoylpyridine thiosemicarbazone Sn(IV) complexes. Eur. J. Med. Chem., 2005, 40(5), 467-472.
[http://dx.doi.org/10.1016/j.ejmech.2005.01.006] [PMID: 15893020]
[59]
Castle, T.C.; Maurer, R.I.; Sowrey, F.E.; Went, M.J.; Reynolds, C.A.; McInnes, E.J.L.; Blower, P.J. Hypoxia-targeting copper bis(selenosemicarbazone) complexes: Comparison with their sulfur analogues. J. Am. Chem. Soc., 2003, 125(33), 10040-10049.
[http://dx.doi.org/10.1021/ja035737d] [PMID: 12914467]
[60]
Todorović, T.R.; Bacchi, A.; Sladić, D.M.; Todorović, N.M.; Božić, T.T.; Radanović, D.D.; Filipović, N.R.; Pelizzi, G.; Anđelković, K.K. Synthesis, characterization and biological activity evaluation of Pt(II), Pd(II), Co(III) and Ni(II) complexes with n-heteroaromatic selenosemicarbazones. Inorg. Chim. Acta, 2009, 362, 3813-3820.
[http://dx.doi.org/10.1016/j.ica.2009.04.047]
[61]
Revenko, M.D.; Prisacari, V.I.; Dizdari, A.V.; Stratulat, E.F.; Corja, I.D.; Proca, L.M. Synthesis, antibacterial, and antifungal activities of 8-quinolinealdehyde chalcogensemicarbazones and their copper(II) complexes. Pharm. Chem. J., 2011, 45, 351-354.
[http://dx.doi.org/10.1007/s11094-011-0631-x]
[62]
Mawat, T.H.; Al-Jeboori, M.J. Synthesis, characterisation, thermal properties and biological activity of coordination compounds of novel selenosemicarbazone ligands. J. Mol. Struct., 2020, 1208, 127876.
[http://dx.doi.org/10.1016/j.molstruc.2020.127876]
[63]
Molter, A.; Rust, J.; Lehmann, C.W.; Deepa, G.; Chiba, P.; Mohr, F. Synthesis, structures and anti-malaria activity of some gold(I) phosphine complexes containing seleno- and thiosemicarbazonato ligands. Dalton Trans., 2011, 40(38), 9810-9820.
[http://dx.doi.org/10.1039/c1dt10885a] [PMID: 21879088]
[64]
McQuade, P.; Martin, K.E.; Castle, T.C.; Went, M.J.; Blower, P.J.; Welch, M.J.; Lewis, J.S. Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents. Nucl. Med. Biol., 2005, 32(2), 147-156.
[http://dx.doi.org/10.1016/j.nucmedbio.2004.10.004] [PMID: 15721760]

Rights & Permissions Print Cite
Article Metrics
53
2
World Chagas Disease
© 2024 Bentham Science Publishers | Privacy Policy